A deep analysis of semaglutide’s phase 3 AD trials shows no cognitive or functional benefit despite biomarker gains, yet ...

AN Alzheimer’s drug which has been rejected for NHS use can slow disease progression by eight years, researchers have claimed ...

Researchers found long-term treatment could delay progression from mild cognitive impairment to moderate Alzheimer’s disease ...

Eli Lilly and Company’s LLY stock has been consistently trading above its 50-day and 200-day simple moving averages (SMAs) ...

Lecanemab is licensed for use in the UK but the spending watchdog deemed the benefits shown in clinical trials were 'too ...

The spending watchdog deemed the drug's benefits 'too small' to justify the cost of making it available on the NHS ...

An Alzheimer’s drug which has been rejected for NHS use can slow disease progression by eight years, researchers have claimed ...

We came across a bullish thesis on Eli Lilly and Company on Pebble Bites’s Substack by Christina Gan. In this article, we ...

Q: I’m 68 and overweight by 45 pounds. Now that GLP-1s are going to be covered by Medicare, I think I will add that to my ...

Home Instead chief executive Martin Jones said: “Dementia has now eclipsed cancer as our greatest health fear for the future.

Q: I'm feeling a little fuzzy-brained and am debating whether to get tested for Alzheimer's. Do you think it's a good idea? -- Cassie R., Knoxville, Tennessee ...

India’s pharmaceutical sector is witnessing global majors deepening their footprint in advanced therapies. The Central Drugs ...